Welcome to DrugBank 4.0! If you prefer, you can still go back to version 3.0.
Identification
NameIron Dextran
Accession NumberDB00893  (APRD01053)
Typesmall molecule
Groupsapproved
Description

Iron dextran is a dark brown, slightly viscous liquid complex of ferric hydroxide and dextran for intravenous or intramuscular use. Iron Dextran is used for the treatment of patients with documented iron deficiency in which oral administration is unsatisfactory or impossible.

Structure
Thumb
Synonyms
SynonymLanguageCode
DexferrumLatinNot Available
Dextran ironNot AvailableNot Available
SaltsNot Available
Brand names
NameCompany
CosmoFerB. Braun
DexIronMylan Pharmaceuticals ULC
FeosolGlaxoSmithKline
ImferonSanofi-Aventis
ProferdexNew River Pharmaceuticals Inc.
Brand mixtures
Brand NameIngredients
Omni 2000tabBeta-Carotene + Biotin + Calcium (Bone Meal) + Choline + Chromium (Yeast) + D-Pantothenic Acid + Folic Acid + Inositol + Iodine (Kelp) + Iron (Iron Dextran Complex) + Magnesium (Magnesium Oxide) + Manganese (Manganese Gluconate) + Molybdenum (Yeast) + Nicotinamide + Potassium (Potassium Gluconate) + Selenium (Yeast) + Vitamin a (Fish Liver Oil) + Vitamin B1 + Vitamin B12 + Vitamin B2 + Vitamin B6 (Pyridoxine Hydrochloride) + Vitamin C (Calcium Ascorbate) + Vitamin C (Vitamin C) + Vitamin D3 + Vitamin E (D-Alpha Tocopheryl Acetate) + Zinc (Zinc Gluconate)
Categories
CAS number9004-66-4
WeightNot Available
Chemical FormulaNot Available
InChI KeyNot Available
InChINot Available
IUPAC NameNot Available
SMILESNot Available
Mass SpecNot Available
Taxonomy
KingdomNot Available
SuperclassNot Available
ClassNot Available
SubclassNot Available
Direct parentNot Available
Alternative parentsNot Available
SubstituentsNot Available
Classification descriptionNot Available
Pharmacology
IndicationFor treatment of patients with documented iron deficiency in whom oral administration is unsatisfactory or impossible. Also used to replenish body iron stores in Non-Dialysis Dependent-Chronic Kidney Disease (NDD-CKD) patients receiving or not receiving erythropoietin and in Hemodialysis Dependent (HDD-CKD) and Peritoneal Dialysis Dependent (PDD-CKD) - Chronic Kidney Disease patients receiving an erythropoietin.
PharmacodynamicsIron dextran is a dark brown, slightly viscous sterile liquid complex of ferric hydroxide and dextran for intravenous or intramuscular use. It is for treatment of patients with documented iron deficiency in whom oral administration is unsatisfactory or impossible. Iron is essential to the formation of hemoglobin and to the function and formation of other heme and nonheme compounds. Untreated depletion of iron stores leads to iron-deficient erythropoiesis and, in turn, to iron deficiency anemia.
Mechanism of actionAfter iron dextran is injected, the circulating iron dextran is removed from the plasma by cells of the reticuloendothelial system, which split the complex into its components of iron and dextran. The iron is immediately bound to the available protein moieties to form hemosiderin or ferritin, the physiological forms of iron, or to a lesser extent to transferrin. This iron which is subject to physiological control replenishes hemoglobin and depleted iron stores.
AbsorptionThe major portion of intramuscular injections of iron dextran is absorbed within 72 hours; most of the remaining iron is absorbed over the ensuing 3 to 4 weeks.
Volume of distributionNot Available
Protein binding100% (after release from dextran)
Metabolism

Dextran, a polyglucose, is either metabolized or excreted.

Route of eliminationDextran, a polyglucose, is either metabolized or excreted.
Half life5 hours (some indications that it can be as long as 10 hours)
ClearanceNot Available
ToxicityLD50 = 500 mg/kg (mouse, IV). Dosages of iron dextran in excess of the requirements for restoration of hemoglobin and replenishment of iron stores may lead to hemosiderosis. Cases of severe, sometimes fatal, allergic reactions (loss of consciousness, collapse, difficulty breathing, hives, swelling, or convulsions) and severe low blood pressure (hypotension) have been reported with the use of iron dextran.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
Property Value Probability
Human Intestinal Absorption Not Available Not Available
Blood Brain Barrier Not Available Not Available
Caco-2 permeable Not Available Not Available
P-glycoprotein substrate Not Available Not Available
P-glycoprotein inhibitor I Not Available Not Available
P-glycoprotein inhibitor II Not Available Not Available
Renal organic cation transporter Not Available Not Available
CYP450 2C9 substrate Not Available Not Available
CYP450 2D6 substrate Not Available Not Available
CYP450 3A4 substrate Not Available Not Available
CYP450 1A2 substrate Not Available Not Available
CYP450 2C9 substrate Not Available Not Available
CYP450 2D6 substrate Not Available Not Available
CYP450 2C19 substrate Not Available Not Available
CYP450 3A4 substrate Not Available Not Available
CYP450 inhibitory promiscuity Not Available Not Available
Ames test Not Available Not Available
Carcinogenicity Not Available Not Available
Biodegradation Not Available Not Available
Rat acute toxicity Not Available Not applicable
hERG inhibition (predictor I) Not Available Not Available
hERG inhibition (predictor II) Not Available Not Available
Pharmacoeconomics
Manufacturers
  • Luitpold pharmaceuticals inc
  • Watson laboratories inc
  • Sanofi aventis us llc
  • New river pharmaceuticals inc
Packagers
Dosage forms
FormRouteStrength
Injection, solutionIntramuscular
Injection, solutionIntravenous
Prices
Unit descriptionCostUnit
Iron dextran comp 100 mg/2 ml38.08USDml
Dexferrum 100 mg/2 ml vial21.6USDml
Dexferrum 50 mg/ml vial21.6USDml
Dexiron 50 mg/ml15.66USDml
Infufer 50 mg/ml15.53USDml
Infed 100 mg/2 ml vial14.44USDml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
CountryPatent NumberApprovedExpires (estimated)
United States56246681995-09-292015-09-29
Properties
Statesolid
Experimental Properties
PropertyValueSource
water solubilitySolubleNot Available
Predicted PropertiesNot Available
Spectra
SpectraNot Available
References
Synthesis Reference

William T. Monte, Laurie Scaggs, “Process for making crystalline iron dextran.” U.S. Patent US5756715, issued 1905.

US5756715
General ReferenceNot Available
External Links
ResourceLink
KEGG DrugD02141
Therapeutic Targets DatabaseDAP001312
PharmGKBPA164764618
Drug Product Database611891
RxListhttp://www.rxlist.com/cgi/generic3/fedex.htm
Drugs.comhttp://www.drugs.com/cdi/iron-dextran.html
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSshow(45.1 KB)
Interactions
Drug Interactions
Drug
AlendronateFormation of non-absorbable complexes
CiprofloxacinFormation of non-absorbable complexes
ClodronateFormation of non-absorbable complexes
DeferiproneDeferiprone may decrease gastrointestinal absorption by chelating to other ions. Interaction is significant so monitor closely.
DemeclocyclineFormation of non-absorbable complexes
DoxycyclineFormation of non-absorbable complexes
EltrombopagLevels of eltrombopag are decreased due to GI inhibition. Separate administration by at least 4 hours.
EnoxacinFormation of non-absorbable complexes
Etidronic acidFormation of non-absorbable complexes
GatifloxacinFormation of non-absorbable complexes
GemifloxacinFormation of non-absorbable complexes
GrepafloxacinFormation of non-absorbable complexes
IbandronateFormation of non-absorbable complexes
L-DOPAIron decreases the absorption of dopa derivatives
LevofloxacinFormation of non-absorbable complexes
LevothyroxineIron decreases the absorption of levothyroxine
LomefloxacinFormation of non-absorbable complexes
MethacyclineFormation of non-absorbable complexes
MethyldopaIron decreases the absorption of dopa derivatives
MinocyclineFormation of non-absorbable complexes
MoxifloxacinFormation of non-absorbable complexes
Mycophenolate mofetilOral iron decreases the absorption of mycophenolate-mofetil
NorfloxacinFormation of non-absorbable complexes
OfloxacinFormation of non-absorbable complexes
OxytetracyclineFormation of non-absorbable complexes
PefloxacinFormation of non-absorbable complexes
PenicillamineThe multivalent agent decreases the effect of penicillamine
RisedronateFormation of non-absorbable complexes
TemafloxacinFormation of non-absorbable complexes
TetracyclineFormation of non-absorbable complexes
TrovafloxacinFormation of non-absorbable complexes
Food InteractionsNot Available

1. Hemoglobin subunit beta

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: activator

Components

Name UniProt ID Details
Hemoglobin subunit beta P68871 Details

References:

  1. Zaric J, Lazic D, Markovic S, Glisin V, Ivanovic Z, Milenkovic P, Popovic Z: Alpha- and beta-globins of the anemic Belgrade laboratory rat. II. The effect of hemin and iron-dextran treatment. Hemoglobin. 1998 May;22(3):231-44. Pubmed
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed

2. Hemoglobin subunit alpha

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: activator

Components

Name UniProt ID Details
Hemoglobin subunit alpha P69905 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed

3. Ferritin heavy chain

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: other

Components

Name UniProt ID Details
Ferritin heavy chain P02794 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

4. Ferritin light chain

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: other

Components

Name UniProt ID Details
Ferritin light chain P02792 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

1. Serotransferrin

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Serotransferrin P02787 Details

References:

  1. Macdougall IC: Strategies for iron supplementation: oral versus intravenous. Kidney Int Suppl. 1999 Mar;69:S61-6. Pubmed
  2. Salahudeen AK, Oliver B, Bower JD, Roberts LJ 2nd: Increase in plasma esterified F2-isoprostanes following intravenous iron infusion in patients on hemodialysis. Kidney Int. 2001 Oct;60(4):1525-31. Pubmed
  3. Pai AB, Boyd AV, McQuade CR, Harford A, Norenberg JP, Zager PG: Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate, and iron sucrose in patients undergoing hemodialysis. Pharmacotherapy. 2007 Mar;27(3):343-50. Pubmed
  4. Jacobs JC, Alexander NM: Colorimetry and constant-potential coulometry determinations of transferrin-bound iron, total iron-binding capacity, and total iron in serum containing iron-dextran, with use of sodium dithionite and alumina columns. Clin Chem. 1990 Oct;36(10):1803-7. Pubmed
  5. Speyer BE, Doney VJ, Fielding J: Transfer of iron from Ferastral and other organic complexes to transferrin as measured by reticulocyte uptake. Scand J Haematol Suppl. 1977;32:215-21. Pubmed

Comments
Drug created on June 13, 2005 07:24 / Updated on October 11, 2013 08:55